Bristol's Early Alzheimer's Research Takes A Different Tack
Executive Summary
Like many other drug makers, Bristol-Myers Squibb has its eye on the potentially lucrative market for a disease-modifying Alzheimer's disease therapy. During an investor meeting March 4, management highlighted the early- to mid-stage Alzheimer's pipeline and outlined one novel approach: targeting the disease earlier before Alzheimer's symptoms develop
You may also be interested in...
Bristol Opens A Phase III Door Into Gamma Secretase As Lilly Closes Another
Whether Bristol-Myers Squibb Co. and others can succeed at bringing a gamma secretase inhibitor to market for the treatment of Alzheimer's disease is far from certain.
Bristol Opens A Phase III Door Into Gamma Secretase As Lilly Closes Another
Whether Bristol-Myers Squibb Co. and others can succeed at bringing a gamma secretase inhibitor to market for the treatment of Alzheimer's disease is far from certain.
FDA Relaxes Safety Requirements For Alzheimer's Trials, But Uncertainty Persists
Sponsors and contract research organizations expressed cautious optimism about FDA's adoption of some of the recommendations of the Alzheimer's Association Research Roundtable Workgroup, but the agency isn't specifying which recommendations it is accepting.